Synergy Between Selective Serotonin Reuptake Inhibitors and α2-Adrenergic Receptor Antagonists in the Treatment of Depression
Pharmacological Rationale and Clinical Significance
Abstract
Selective serotonin reuptake inhibitors (SSRIs) represent the most commonly used pharmacotherapeutic strategy in the treatment of major depressive disorder. However, a substantial proportion of patients do not achieve remission, develop only a partial response, or remain burdened by residual symptoms, most commonly insomnia, anxiety, loss of appetite, sexual dysfunction, and gastrointestinal complaints. Combining SSRI antidepressants with α2-adrenergic receptor antagonists, among which mirtazapine is the most important clinical representative, is a pharmacologically rational approach because it simultaneously enhances serotonergic transmission through complementary mechanisms and adds a noradrenergic component to antidepressant action. While SSRIs increase the synaptic availability of serotonin by inhibiting the serotonin transporter, mirtazapine increases the release of noradrenaline and serotonin by blocking presynaptic α2-autoreceptors and α2-heteroreceptors. In addition, antagonism of 5-HT2 and 5-HT3 receptors functionally directs serotonergic transmission toward 5-HT1A-mediated effects and may contribute to better tolerability compared with pure serotonergic potentiation. The clinical significance of this combination is most evident in patients with a partial response to SSRIs, depression accompanied by insomnia, anxiety, loss of appetite, or adverse effects of SSRI therapy. However, although randomized studies and meta-analyses generally indicate greater efficacy of combinations that include α2-receptor antagonists, some studies, such as the MIR trial, did not demonstrate a significant benefit of adding mirtazapine to ongoing SSRI therapy in all patients with SSRI-resistant depression. Therefore, the combination of an SSRI and mirtazapine should be regarded as a personalized, symptom-guided, and pharmacologically grounded strategy, rather than as a universally superior therapeutic approach.
References
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366.
Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439-1445.
Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22-27.
Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259-266.
Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459-525.
Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian Network for Mood and Anxiety Treatments clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. Can J Psychiatry. 2016;61(9):540-560.
de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57 Suppl 4:19-25.
Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249-264.
Landy K, Rosani A, Estevez R. Escitalopram. In: StatPearls. Treasure Island: StatPearls Publishing; 2024.
Sánchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol. 2014;29(4):185-196.
Zhong H, Haddjeri N, Sánchez C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter: a review of current understanding of its mechanism of action. Psychopharmacology. 2012;219(1):1-13.
Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 1994;15(7):220-226.
Haddjeri N, Blier P, de Montigny C. Effect of the α2-adrenoceptor antagonist mirtazapine on the 5-HT system in the rat brain. Neuropharmacology. 1996;35(12):1687-1697.
Alam A, Voronovich Z, Carley JA. A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord. 2013;15(5):PCC.13r01525.
Jilani TN, Gibbons JR, Faizy RM, Saadabadi A. Mirtazapine. In: StatPearls. Treasure Island: StatPearls Publishing; 2024.
Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69 Suppl E1:4-7.
Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998;51(3):267-285.
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-758.
Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, Hébert C, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009;19(7):457-465.
Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281-288.
Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, et al. Combining medications to enhance depression outcomes: acute and long-term outcomes of the CO-MED randomized trial. Am J Psychiatry. 2011;168(7):689-701.
Kessler DS, MacNeill SJ, Tallon D, Lewis G, Peters TJ, Hollingworth W, et al. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial. BMJ. 2018;363:k4218.
Kessler D, Burns A, Tallon D, Lewis G, MacNeill S, Round J, et al. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. Health Technol Assess. 2018;22(63):1-136.
Henssler J, Bschor T, Baethge C. Combining antidepressants in acute treatment of depression: a meta-analysis of 38 studies including 4511 patients. Can J Psychiatry. 2016;61(1):29-43.
Henssler J, Alexander D, Schwarzer G, Bschor T, Baethge C. Combining antidepressants vs antidepressant monotherapy for treatment of patients with acute depression: a systematic review and meta-analysis. JAMA Psychiatry. 2022;79(4):300-312.
Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry. 2001;62 Suppl 3:10-21.
Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120.
Lam RW, Kennedy SH, Adams C, Bahji A, Beaulieu S, Bhat V, et al. Canadian Network for Mood and Anxiety Treatments 2023 update on clinical guidelines for management of major depressive disorder in adults. Can J Psychiatry. 2024;69(9):641-687.
Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2021;55(1):7-117.
Copyright (c) 2026 Engrami
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.